PTC Therapeutics (PTCT) announced that Sephience has been approved by the Japanese Ministry of Health, Labor and Welfare for the treatment of children and adults living with phenylketonuria. The label includes individuals of all ages and the full spectrum of disease severity. PTC will now engage in pricing discussions which are expected to conclude in Q1 2026, with launch occurring shortly thereafter.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strong Growth Potential Driven by R&D Expertise and Successful Sephience Launch
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
- Cadrenal Therapeutics appoints Lee Golden to board of directors
- PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- SanDisk Stock (SNDK) Jumps on S&P 500 Inclusion and Price Target Upgrades